Gilead fails late-stage trial for Trodelvy in first-line breast cancer

[Maker Of Coronavirus Trial Drug Remdesivir, Gilead Sciences. Inc., Reports Positive Data Coming From Trials]
Justin Sullivan/Getty Images News

Gilead Sciences (GILD [https://seekingalpha.com/symbol/GILD]) announced on Friday that a Phase 3 trial for its FDA-approved antibody-drug conjugate Trodelvy failed in a Phase 3 trial, which tested it as a first-line option for certain patients with breast cancer who have undergone prior endocrine therapy.

Based on data from its Phase 3 ASCENT-07 study, the Foster City, California-based biotech said Trodelvy didn’t reach the trial’s primary endpoint related to patients’ progression-free survival (PFS).

The global trial was designed to evaluate Trodelvy versus chemotherapy in patients with locally advanced, inoperable, or HR+/HER2-negative breast cancer, the most common breast cancer subtype, which accounts for nearly ~70% of cases.

At the time of the analysis, the data for overall survival, a key secondary endpoint of ASCENT-07, were not mature, the company said, adding, however, that there was an early favorable trend supporting OS benefit in Trodelvy-treated patients compared to those on chemotherapy.

Trodelvy is currently approved as a late-line option for triple-negative breast cancer and HER2-negative breast cancer in the U.S. [https://seekingalpha.com/pr/20298866-gilead-provides-update-on-phase-3-ascentminus-07-study]

MORE ON GILEAD SCIENCES

* Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4835944-gilead-sciences-inc-gild-q3-2025-earnings-call-transcript]
* Gilead Sciences, Inc. 2025 Q3 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4835945-gilead-sciences-inc-2025-q3-results-earnings-call-presentation]
* What To Expect From Gilead In Q3 2025 [https://seekingalpha.com/article/4833109-what-to-expect-from-gilead-in-q3-2025]
* Gilead raises 2025 HIV revenue growth outlook to 5% as Biktarvy and Descovy drive momentum [https://seekingalpha.com/news/4512038-gilead-raises-2025-hiv-revenue-growth-outlook-to-5-percent-as-biktarvy-and-descovy-drive]
* Gilead drops despite narrowing 2025 outlook ranges on weak Veklury sales [https://seekingalpha.com/news/4511785-gilead-drops-despite-narrowing-2025-outlook-ranges-weak-veklury-sales]